Modulation of the Prostate Cancer Resistance Factor Hsp27 by the Chemotherapeutic Drugs Abiraterone, Cabazitaxel, Docetaxel and Enzalutamide
Anticancer Research · 2024
DOI: 10.21873/anticanres.17093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Jennifer H S Küster und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Gynecological Oncology, University Hospital Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: Taxoids, Docetaxel, Phenylthiohydantoin, Benzamides. Die Arbeit wurde bisher 4-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology and Gynecological Oncology, University Hospital Bonn, Bonn, Germany.
- Department of Urology, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
- Department of Medicine, Israelite Hospital Hamburg, Hamburg, Germany.
- Department of General, Visceral and Thorax Surgery, Bundeswehr Hospital Berlin, Berlin, Germany.
- Department of Gynecology and Gynecological Oncology, University Hospital Bonn, Bonn, Germany; matthias.stope@ukbonn.de.
Zitieren
APA
Küster, J. H. S., Erb, H. H. H., Ahrend, H., Abazid, A., & Stope, M. B. (2024). Modulation of the Prostate Cancer Resistance Factor Hsp27 by the Chemotherapeutic Drugs Abiraterone, Cabazitaxel, Docetaxel and Enzalutamide. Anticancer Research. https://doi.org/10.21873/anticanres.17093
Vancouver
Küster JHS, Erb HHH, Ahrend H, Abazid A, Stope MB. Modulation of the Prostate Cancer Resistance Factor Hsp27 by the Chemotherapeutic Drugs Abiraterone, Cabazitaxel, Docetaxel and Enzalutamide. Anticancer Research. 2024. doi:10.21873/anticanres.17093
BibTeX
@article{Kster2024,
author = {Küster, Jennifer H S and Erb, Holger H H and Ahrend, Hannes and Abazid, Alexander and Stope, Matthias B},
title = {Modulation of the Prostate Cancer Resistance Factor Hsp27 by the Chemotherapeutic Drugs Abiraterone, Cabazitaxel, Docetaxel and Enzalutamide},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.17093}
}
EUVIMED